Nalaganje...
Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage
BACKGROUND: Phase I/II placebo-controlled clinical trials of recombinant Factor VIIa (rFVIIa) suggested that administration of rFVIIa within 4 hours after onset of intracerebral hemorrhage (ICH) is safe, limits ICH growth, and improves outcomes. We sought to determine the cost-effectiveness of rFVII...
Shranjeno v:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2008
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2397434/ https://ncbi.nlm.nih.gov/pubmed/18489750 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2377-8-17 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|